1Bennish ML,Khan WA,Begum M,et al.Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh[J].Clin Infect Dis,2006,42(3):356-362.
2Ikeda K,Ida O,Kimoto K,et al.Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection[J].Clin Nephrol,1999,52(6):357-362.
3Shiomi M,Togawa M,Fujita K,et al.Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7[J].Pediatr Int,1999,41(2):228-232.
4Higami S,Nishimoto K,Kawamura T,et al.Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak[J].Kansenshogaku Zasshi,1998,72(3):266-272.
5Isogai E,Isogai H,Hayashi,et al.Effect of antibiotics,LVFX and FOM,on a mouse model with Escherichia coli O157 infection[J].Microbiol Immunol,2000,44(1):89.
6Ohara T,Kojio S,Taneike I,et al.Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response[J].Antimicrob Agents Chemother,2002,46(11):3478-3483.
7Basualdo W,Arbo A.Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children[J].Pediatr Infect Dis J,2003,22(4),374-377.
8Kurioka T,Yunou Y,Harada H,et al.Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition[J].Eur J Clin Microbiol Infect Dis,1999,18(8):561-571.
9Wong CS,Jelacic S,Habeeb RL,et al.The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections[J].N Engl J Med,2000,342(26):1930-1936.
10Zimmerhackl LB.E.coli,antibiotics,and the hemolytic-uremic syndrome[J].N Engl J Med,2000,342(26):1990-1991.
二级参考文献15
1Zhang YW, Shen Y, Feld LG, et al. Changing pattern of glomerular disease at Beijing Children' s Hospital. Clin Pediatr, 1994, 33(9) : 542- 547.
2Moghal NE, Ferreira MA, Howie AJ, et al. The late histologic findings in diarrhea-associated hemolytic uremic syndrome.J Pediatr, 1998, 133(2) : 220- 223.
3van Geet C, Proesmans W, Arnout J, et al. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int, 1998, 54(4) : 1324- 1330.
4Yoshioka K, Yagi K, Moriguchi N, et al. Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia Coli 0157:H7 infection: Experience of an outbreak in Sakai city, 1996. Pediatr Int, 1999, 41(2) : 223- 227.
5Heuvelink AE, Vandekar NC, van der Velden TJ, et al. Children with hemolytic uremic syndrome. Pediatr Infect Dis J, 1999, 18(8) : 709- 714.
6Banatvala N, Griffin PM, Greene KD, et al. The United States National prospective hemolytic uremic syndrome study:Serologic clinical and epidemiologic findings.J Infect Dis,2001, 183(7) : 1063-1070.
7Decludt B, Bouvet P, Mariani-Kurkdjian P, et al. Hemolytic-uremic syndrome and Shiga toxin-producing Escherichia Coli infection in children in France. Epidemiol Infect, 2000, 124(2) : 215- 220.
8Caletti MG, Gallo G, Gianantonio CA. Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol, 1996, 10(6) : 687-692.
10Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia Coli O157 : H7 infection. N Engl J Med, 2000, 342(26) : 1990- 1991.
2Seto EY, Soller JA, Colford JM Jr. Strategies to reduce person - to - person transmission during widespread Escherichia coli O157 :H7 outbreak. Emerg Infect Dis,2007,13 ( 6 ) : 860 - 866.
3Noris M, Remuzzi G, Hemolytic Uremic Syndrome. J Am Soc Nephrol, 2005,16(5 ) : 1035 - 1050.
4MacConnachie AA, Todd WT. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection. Curr Opin Infect Dis ,2004 ,17(5) :479 -482.
5Trachtman H,Cnaan A, Christen E ,et al. Effect of an oral Shiga toxin -binding agent on diarrhea- associated hemolytic uremic syndrome in children : a randomized controlled trial. JAMA, 2003, 290 ( 10 ) :1337 - 1344.
6Pinyon RA,Paton JC, Paton AW, et al. Refinement of a therapeutic Shiga toxin - binding probiotic for human trials. J Infect Dis, 2004, 189(9) :1547 - 1555.
7Neri P, Nagano SI, Yokoyama S, et al. Neutralizing activity of polyvalent Gb3, Gb2 and galacto - trehalose models against Shiga toxins. Microbiol Immunol,2007,51 (6) :581 - 592.
8Kuribayashi T, Seita T, Fukuyama M, et al. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157 :H7 in mice. J Infect Chemother,2006, 12 (5) :251 - 256.
9Wen SX, Teel LD, Judge NA, et al. A plant - based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A,2006, 103(18) :7082 -7087.
10Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli 0157 O - specific polysaccharide conjugate vaccine in 2 -5 -year - old children. J Infect Dis,2006, 193(4) : 515 - 521.
